Special Purpose Acquisition Companies have emerged as one of the hottest financing options for life science companies. In 2020, over 200 IPOs raised $83B through SPACS — 2021 is on track to far exceed that rate.
The traditional IPO process requires a significant amount of time and resources that not all emerging companies can spare. Positioned as a superior, faster alternative, not only do SPACs allow for growth companies to become public without the market exposure and execution risk of a typical IPO process – they help institutional investors position into their highest priority IPO investment targets. But what are the pros and cons of the SPAC vehicle as it continues to evolve? It is a short-term structural finance fad, or is it here to stay and changing IPOs for the long term?
Back Bay Life Science Advisors’ investment banking team will lead a discussion on the SPAC structures, offering a current snapshot and a forward look at this evolving asset class. They will be joined by life science SPAC experts who will share their experiences and forward-looking predictions.
Date: June 17, 2021
Time: 16:30 – 17:45 CEST/ 10:30 am – 11:45 am EDT